Luiz R Travassos Selected Research

Complementarity Determining Regions (Complementarity Determining Region)

1/2019	Molecular, Biological and Structural Features of VL CDR-1 Rb44 Peptide, Which Targets the Microtubule Network in Melanoma Cells.
11/2016	The Ig VH complementarity-determining region 3-containing Rb9 peptide, inhibits melanoma cells migration and invasion by interactions with Hsp90 and an adhesion G-protein coupled receptor.
9/2015	A novel microtubule de-stabilizing complementarity-determining region C36L1 peptide displays antitumor activity against melanoma in vitro and in vivo.
4/2012	β-Actin-binding complementarity-determining region 2 of variable heavy chain from monoclonal antibody C7 induces apoptosis in several human tumor cells and is protective against metastatic melanoma.
8/2010	Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Luiz R Travassos Research Topics

Disease

37	Melanoma (Melanoma, Malignant) 01/2022 - 11/2003
33	Neoplasms (Cancer) 01/2022 - 01/2002
18	Paracoccidioidomycosis (South American Blastomycosis) 09/2020 - 11/2002
15	Infections 01/2017 - 03/2002
8	Neoplasm Metastasis (Metastasis) 01/2022 - 04/2012
4	Mycoses (Diseases, Fungus) 02/2020 - 04/2008
2	Granuloma 01/2016 - 01/2012
2	Wilms Tumor (Wilm's Tumor) 12/2014 - 01/2014
2	Experimental Melanoma 04/2014 - 01/2012
2	Inflammation (Inflammations) 01/2012 - 10/2007
1	Necrosis 01/2022
1	Fibrosis (Cirrhosis) 01/2012

Drug/Important Bio-Agent (IBA)

34	Peptides (Polypeptides)IBA 01/2022 - 11/2004
10	VaccinesIBA 09/2020 - 10/2008
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2002
6	Pharmaceutical PreparationsIBA 07/2021 - 09/2008
6	AntibodiesIBA 01/2016 - 01/2008
5	Monoclonal AntibodiesIBA 02/2020 - 10/2007
5	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 11/2003
5	Complementarity Determining Regions (Complementarity Determining Region)IBA 01/2019 - 08/2010
5	AntigensIBA 01/2019 - 11/2002
4	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2016 - 01/2012
4	DNA VaccinesIBA 03/2013 - 04/2008
3	ChromatinIBA 01/2022 - 07/2011
3	Peptide Hydrolases (Proteases)FDA Link 01/2019 - 01/2012
3	Biological ProductsIBA 01/2019 - 01/2011
3	Transcription Factors (Transcription Factor)IBA 01/2019 - 01/2014
3	Immunoglobulins (Immunoglobulin)IBA 01/2019 - 01/2008
3	Protein Subunit VaccinesIBA 01/2017 - 04/2008
3	Therapeutic UsesIBA 01/2017 - 01/2012
3	EnzymesIBA 01/2014 - 07/2007
3	tesmilifene (DPPE)IBA 07/2011 - 11/2003
3	matrigelIBA 04/2011 - 07/2007
2	Cyclic PeptidesIBA 01/2019 - 08/2010
2	Caspase 3 (Caspase-3)IBA 01/2019 - 11/2015
2	Cysteine Proteases (Cysteine Protease)IBA 01/2019 - 09/2007
2	Metalloproteases (Metalloproteinases)IBA 07/2016 - 01/2014
2	AcidsIBA 09/2015 - 01/2014
2	DNA (Deoxyribonucleic Acid)IBA 06/2015 - 07/2011
2	FlagellinIBA 01/2015 - 01/2012
2	LigandsIBA 01/2015 - 11/2003
2	Trimethoprim (Proloprim)FDA LinkGeneric 10/2014 - 03/2010
2	Sulfamethoxazole FDA LinkGeneric 10/2014 - 03/2010
2	Immunoglobulin G (IgG)IBA 01/2014 - 08/2010
2	Interleukin-12 (IL 12)IBA 10/2012 - 09/2008
2	Interleukin-4 (Interleukin 4)IBA 10/2012 - 08/2003
2	N-desmethylpheniramineIBA 07/2011 - 07/2011
2	MART-1 AntigenIBA 12/2010 - 04/2005
2	gomesinIBA 09/2009 - 01/2008
2	SuspensionsIBA 09/2007 - 08/2003
2	KininsIBA 07/2007 - 04/2005
2	CytokinesIBA 08/2003 - 10/2002
1	Immune Checkpoint InhibitorsIBA 12/2020
1	NivolumabIBA 12/2020
1	IpilimumabIBA 12/2020
1	Lactic Acid (Lactate)FDA LinkGeneric 12/2020
1	ChitosanIBA 09/2020
1	Fungal VaccinesIBA 02/2020
1	Cysteine Proteinase InhibitorsIBA 01/2019
1	CathepsinsIBA 01/2019
1	TelluriumIBA 01/2019
1	Caspase 9IBA 01/2019
1	Indicators and Reagents (Reagents)IBA 01/2019
1	Phosphates (Orthophosphate)IBA 01/2019
1	Conditioned Culture MediaIBA 01/2019
1	Carrier Proteins (Binding Protein)IBA 01/2019
1	K237 peptideIBA 09/2017
1	polypeptide CIBA 09/2017
1	EpitopesIBA 01/2017
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 11/2016
1	Actins (F Actin)IBA 01/2016
1	GlycolipidsIBA 01/2016
1	campheneIBA 11/2015
1	Monoterpenes (Monoterpenoids)IBA 11/2015
1	Petroleum (Crude Oil)IBA 11/2015
1	Volatile Oils (Essential Oils)IBA 11/2015
1	HMGB1 Protein (HMG1)IBA 11/2015
1	CalreticulinIBA 11/2015
1	FITC-annexin A5IBA 06/2015
1	mastoparanIBA 06/2015
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2015
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2015
1	ZincIBA 12/2014
1	Itraconazole (Sporanox)FDA LinkGeneric 10/2014
1	HydrocarbonsIBA 04/2014
1	HeptanesIBA 04/2014
1	octacosaneIBA 04/2014
1	PhosphatidylserinesIBA 04/2014
1	GalactosidasesIBA 01/2014
1	Arginine (L-Arginine)FDA Link 01/2014
1	Cytostatic AgentsIBA 01/2014
1	Complement System Proteins (Complement)IBA 01/2014
1	Lysine (L-Lysine)FDA Link 01/2014
1	Interleukin-10 (Interleukin 10)IBA 10/2012
1	Polysaccharides (Glycans)IBA 09/2012
1	AmidesIBA 04/2012

Therapy/Procedure

15	Therapeutics 07/2021 - 08/2010
6	Immunotherapy 02/2020 - 04/2008
6	Drug Therapy (Chemotherapy) 01/2017 - 04/2008
2	Investigational Therapies (Experimental Therapy) 09/2020 - 01/2019